samedan logo
 
 
 
spacer
home > ebr > spring 2004 > paediatric clinical trials - the challenges facing central laboratories
PUBLICATIONS
European Biopharmaceutical Review

Paediatric Clinical Trials - The Challenges Facing Central Laboratories

With changes in legislation both in the US and Europe there is now more pressure on pharmaceutical companies to perform paediatric clinical studies. Most drugs prescribed for children have not been tested in children - only 20 to 30 per cent of drugs approved by the Food and Drug Administration are labelled for paediatric use. Doctors have routinely given drugs to children 'off label', which means the drug has not been studied in children in adequate, well-controlled clinical trials. The drug development industry will have to gear itself up to perform more paediatric studies in the coming years. The purpose of this article is to encourage discussion about services that may be required of central laboratories to support paediatric work. In the past, most central laboratories have not had to cater for many studies involving children. There are various central laboratory services that need to be added or modified to accommodate the demands of paediatric studies. Here are a few examples of the areas that should be reviewed.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Kirk Daly, European Sales Director for CentraLabS Clinical Research

Kirk Daly studied Medical Technology in South Africa and specialised in Biochemistry. He has been involved in various business development roles with central laboratories and CROs over the past 13 years. He is currently European Sales Director for CentraLabS Clinical Research, with the provision of services for paediatric trials as an area of special focus.

spacer
Kirk Daly
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Carterra Announces Successful Immunity Monitoring of COVID-19 Patients Using a SARS-CoV-2 Label-free Assay

Carterra Inc., the world leader in high-throughput antibody screening and characterization, has announced the availability of a highly accurate assay for simultaneously measuring the concentration and binding of IgG, IgM, and IgA antibodies to the Receptor Binding Domain (RBD) of SARS-CoV-2.
More info >>

White Papers

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

DiagnostikNet-BB

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement